DBV Technologies Granted US Patents for Allergen Delivery System VIASKIN
DBV Technologies’ VIASKIN is the first device especially developed for EPicutaneous ImmunoTherapy (EPIT). VIASKIN enhances hydration of the surface of the skin and allows the diffusion of allergens into the superficial layers, so that they can interact with the skin’s immune network in order to desensitize food allergy patients safely without any risk of systemic reactions. VIASKIN is applied on intact skin and is completely non-invasive.
Commenting on the announcement, DBV Technologies’ CEO and Co-Founder, Pierre-Henri Benhamou, MD said: “We are delighted to have secured two patents central to our VIASKIN technology, which further strengthen the competitiveness of our core technology and we are delighted this protection has been granted for an extended period. To date VIASKIN is successfully marketed as a diagnostic product but has also shown huge promise as a safe, painless and effective therapy for food allergy desensitization.”
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.